Federal Register / Vol. 71, No. 149 / Thursday, August 3, 2006 / Notices 44031 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the National Coordinator for 

Health Information Technology; 

American Health Information 

Community Electronic Health Record 

Workgroup Meeting 

ACTION: Announcement of meeting. 

SUMMARY: This notice announces the 

eighth meeting of the American Health 

Information Community Electronic 

Health Record Workgroup in accordance 

with the Federal Advisory Committee 

Act (Pub. L. 92–463, 5 U.S.C., App.) 

DATES: August 15, 2006 from 1 p.m. to 

5 p.m. 

ADDRESSES: Mary C. Switzer Building 

(330 C Street, SW., Washington, DC 

20201), Conference Room 4090 (please 

bring photo ID for entry to a Federal 

building). 

FOR FURTHER INFORMATION: http:// 

www.hhs.gov/healthit/ahic/ 

bio_main.html. 

SUPPLEMENTARY INFORMATION: The 

meeting will be available via Web cast 

at http://www.eventcenterlive.com/ 

cfmx/ec/login/login1.cfm.?BID=67. 

Dated: July 25, 2006. 

Judith Sparrow, 

Director, American Health Information 

Community, Office of Programs and 

Coordination, Office of the National 

Coordinator for Health Information 

Technology. 

[FR Doc. 06–6662 Filed 8–2–06; 8:45 am] 

BILLING CODE 4150–24–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the National Coordinator for 

Health Information Technology; 

American Health Information 

Community Chronic Care Workgroup 

Meeting 

ACTION: Announcement of meeting. 

SUMMARY: This notice announces the 

eighth meeting of the American Health 

Information Community Chronic Care 

Workgroup in accordance with the 

Federal Advisory Committee Act (Pub. 

L. 92–463, 5 U.S., App.). 

DATES: August 16, 2006 from 1 p.m. to 

5 p.m. 

ADDRESSES: Mary C. Switzer Building 

(330 C Street, SW., Washington, DC 

20201), Conference Room 4090 (please 

bring photo ID for entry to a Federal 

building). 

FOR FURTHER INFORMATION CONTACT: 

http://www.hhs.gov/healthit/ahic/ 

bio_main.html. 

SUPPLEMENTARY INFORMATION: The 

meeting will be available via Web cast 

at http://www.eventcenterlive.com/ 

cfmx/ec/login/login1.cfm?BID=67. 

Dated: July 25, 2006. 

Judith Sparrow, 

Director, American Health Information 

Community, Office of Programs and 

Coordination, Office of the National 

Coordinator for Health Information 

Technology. 

[FR Doc. 06–6661 Filed 8–2–06; 8:45am] 

BILLING CODE 4150–24–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention (CDC) 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel: Non-Pharmaceutical 

Interventions for Pandemic Influenza, 

Request for Applications (RFA) CI06–

010 

Correction: This notice was published 

in the Federal Register on July 13, 2006, 

Volume 71, Number 134, page 39683. 

The date has been changed due to 

reviewer’s conflict with the original 

date. The meeting will be held on 

August 28, 2006. 

Title: Non-Pharmaceutical 

Interventions for Pandemic Influenza, 

RFA CI06–010. 

Contact Person for more Information: 

Felix Rogers, Ph.D., Scientific Review 

Administrator, National Immunization 

Program, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE., 

MS E–05, Atlanta, GA 30333, Telephone 

404.639.6101. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: July 27, 2006. 

Alvin Hall, 

Director, Management Analysis and Services 

Office Centers for Disease Control and 

Prevention. 

[FR Doc. E6–12542 Filed 8–2–06; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2006E–0189] 

Determination of Regulatory Review 

Period for Purposes of Patent 

Extension; IPLEX 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) has determined 

the regulatory review period for IPLEX 

and is publishing this notice of that 

determination as required by law. FDA 

has made the determination because of 

the submission of an application to the 

Director of Patents and Trademarks, 

Department of Commerce, for the 

extension of a patent which claims that 

human drug product. 

ADDRESSES: Submit written comments 

and petitions to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. Submit 

electronic comments to http:// 

www.fda.gov/dockets/ecomments. 

FOR FURTHER INFORMATION CONTACT: 

Beverly Friedman, Office of Regulatory 

Policy (HFD–7), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–594–2041. 

SUPPLEMENTARY INFORMATION: The Drug 

Price Competition and Patent Term 

Restoration Act of 1984 (Public Law 98–

417) and the Generic Animal Drug and 

Patent Term Restoration Act (Public 

Law 100–670) generally provide that a 

patent may be extended for a period of 

up to 5 years so long as the patented 

item (human drug product, animal drug 

product, medical device, food additive, 

or color additive) was subject to 

regulatory review by FDA before the 

item was marketed. Under these acts, a 

product’s regulatory review period 

forms the basis for determining the 

amount of extension an applicant may 

receive. 

A regulatory review period consists of 

two periods of time: A testing phase and 

an approval phase. For human drug 

products, the testing phase begins when 

the exemption to permit the clinical 

investigations of the human drug 

product becomes effective and runs 

until the approval phase begins. The 

approval phase starts with the initial 

submission of an application to market 

the human drug product and continues 

until FDA grants permission to market 

the drug product. Although only a 

portion of a regulatory review period 


hsrobinson on PROD1PC69 with NOTICES